Living with a rare genetic disorder like mannosidosis can be challenging, but modern therapy offers new hope. With targeted treatment options, individuals affected by this condition can now manage symptoms more effectively and improve their overall quality of life. Let’s explore how therapy for mannosidosis is changing lives and opening doors to a healthier future.
Mannosidosis is an inherited disorder, categorised into two types: alpha-mannosidosis and beta-mannosidosis. Here are the different therapy options for both these types:
For patients with rare alpha-mannosidosis, the first enzyme replacement therapy is considered the most effective. Approved by the FDA, Lamzede (velmanase alfa) works like the missing enzyme alpha-mannosidase, helping the body's cells function normally. Patients take Lamzede as a 10mg injection once a week to treat symptoms of the non-central nervous system.
To treat beta-mannosidosis, a team of healthcare professionals, which included paediatricians and physicians, play a key role in diagnosing and managing neurological and hearing-related issues. They suggest several therapies for addressing different issues, such as:
The annual cost of Lamzede (velmanase alfa) enzyme replacement therapy in India is approximately ₹70–75 lakh, based on weekly dosing and current market rates. Enzyme replacement therapy involves 26 vials of the medicine annually.
Disclaimer: The cost information is sourced from various references and may vary significantly. Consulting renowned professionals for accurate and up-to-date details on Mannosidosis treatment costs would be a wise decision.
The Indian government has increased the grant from Rs. 20 lakh to Rs. 50 lakh in March 2021 under the National Policy for Rare Diseases (NPRD), issued by the Ministry of Health & Family Welfare.
Note that this financial support to treat any category of rare health conditions would not be limited to BPL families. About 40% of the population is eligible according to the norms of Pradhan Mantri Jan Arogya Yojana. However, only individuals who opt for government hospitals can access this facility.